GAITHERSBURG, Md., March 11, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today provided a business update and financial ...
Fourth quarter revenue up 16% year-over-year, $26.9M of secured debt eliminated, and total cash and escrowed proceeds of $44.3M at year-end GAITHERSBURG, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Elutia ...
– Base biologic matrix NXT-41 submitted to FDA; on track for anticipated FDA clearance in second half of 2026 and full NXT-41x clearance in 1H27 – Fourth Quarter 2025 Financial ResultsNet sales and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results